CDR-106

N/A

Report date: 2026/03/19 16:59:31

Base Information

Drug NameCDR-106

Drug Alias Nameanti-CD3/anti-pMHC class I T-cell engager (CDR-Life)CDR-106

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsHistocompatibility antigens class I modulators

TargetsHistocompatibility antigens class IT cell surface glycoprotein CD3

Therapy Area/IndicationsPancreatic NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCDR-Life Inc

China Registration ClassN/A

Develop Information

Active CompaniesCDR-Life Inc

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A